Drug Profile
Acamprosate - Confluence Pharmaceuticals
Alternative Names: AOP 2020; Campral; SF 679/SF 775; SF 999Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Confluence Pharmaceuticals
- Developer Cincinnati Children's Hospital Medical Center; Indiana University; Rush University
- Class Alkanesulfonic acids; Behavioural disorder therapies; Drug withdrawal therapies; Small molecules
- Mechanism of Action GABA A receptor agonists; Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Fragile X syndrome
- Phase II Autistic disorder
Most Recent Events
- 07 Dec 2022 No development reported - Phase-II/III for Fragile X syndrome (In adolescents, In children, In adults) in USA (PO) (NCT01911455)
- 08 Nov 2018 Rush University completes a phase II/III trial in Fragile X syndrome (In adolescents, In adults, In children) in USA(PO) (NCT01911455)
- 06 Feb 2018 Chemical structure information added